Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: A nationwide retrospective cohort study ( J-ASPECT study)

the J-ASPECT Study Collaborators

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Objectives: To elucidate the association between antiplatelet use in patients with non-haemorrhagic moyamoya disease before hospital admission and good functional status on admission in Japan. Design: Retrospective, multicentre, non-randomised, observational study. Setting: Nationwide registry data in Japan. Participants: A total of 1925 patients with nonhaemorrhagic moyamoya disease admitted between 1 April 2012 and 31 March 2014 in Japan. Main outcome measure: We performed propensity score-matched analysis to examine the association between prehospital antiplatelet use and no significant disability on hospital admission, as defined by a modified Rankin Scale score of 0 or 1. Results: Propensity-matched patients who received prehospital antiplatelet drugs were associated with a good outcome on hospital admission (OR adjusted for all covariates, 3.82; 95% CI 1.22 to 11.99) compared with those who did not receive antiplatelet drugs prior to hospital admission. Conclusions: Prehospital antiplatelet use was significantly associated with good functional status on hospital admission among patients with nonhaemorrhagic moyamoya disease in Japan. Our results suggest that prehospital antiplatelet use should be considered when evaluating outcomes of patients with non-haemorrhagic moyamoya disease.

Original languageEnglish
Article numbere009942
JournalBMJ open
Volume6
Issue number3
DOIs
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: A nationwide retrospective cohort study ( J-ASPECT study)'. Together they form a unique fingerprint.

Cite this